Lower gastrointestinals study

In 2019, the global Gastrointestinal market size was $34 billion. Inside that market, the Lower Gastrointestinal category – which includes laxative products, antidiarrheals, antispasmodics & IBS remedies (plus GI-oriented probiotics) – is one of one of the most dynamic, as its growth currently outperforms the rest of the consumer health market, reaching nearly 7% in 2018 and adding $653mn in net global sales. 

According to recent market research studies, key growth drivers include high-profile consumer promotions, new product developments (including new formats, increased efficacy, multi-symptom presentations) and pharmacists’ brand recommendations (advice given by pharmacists on specific brands when consumers ask for a Gastrointestinal medicine).

As with any other go-to-market strategy in pharma (*), brand recommendation is thus crucial for brands that want to increase market penetration and sales. Our study reveals the most recommended Lower GIs brands across 7 European countries – Italy, UK, Spain, France, Poland, Germany and Russia – in more than 700 pharmacies.

In the last section of our report, we have provided detailed insights on how to translate that data into action by leveraging the innovative “Lean Go-to-Market” model, which can boost your field force productivity and allow them to be 100% focused on selling.